Regeneron Pharmaceuticals has revealed compelling results from a late-stage trial focused on treating high-risk cutaneous squamous cell carcinoma. The study involved patients who had undergone surgery and radiation therapy. An impressive 85% of these patients showed no signs of cancer recurrence after receiving the adjuvant treatment. This treatment targets those with a high risk of the cancer returning, offering new hope in managing this aggressive form of skin cancer. The trial’s success rate underscores the potential of this new approach in significantly reducing the likelihood of cancer recurrence, providing a beacon of hope for those affected by this condition.
Source: seekingalpha.com
